Omda (OMDA) Aandelenoverzicht
Omda AS levert softwareoplossingen voor de gezondheidszorg in Noorwegen, Zweden, Denemarken, Finland en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
OMDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omda AS Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | NOK 37.00 |
| 52 Week Hoogtepunt | NOK 56.60 |
| 52 Week Laag | NOK 33.00 |
| Bèta | 0.42 |
| 1 maand verandering | 4.82% |
| 3 maanden verandering | -7.50% |
| 1 Jaar Verandering | -26.59% |
| 3 jaar verandering | -10.19% |
| 5 jaar verandering | -61.70% |
| Verandering sinds IPO | -55.42% |
Recent nieuws en updates
Narratiefupdate • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.Analyseartikel • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...Narratiefupdate • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Recent updates
Narratiefupdate • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.Analyseartikel • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...Narratiefupdate • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Narratiefupdate • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Narratiefupdate • Apr 06
OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside
The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.Narratiefupdate • Mar 23
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside
Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.Narratiefupdate • Mar 08
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside
Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.Narratiefupdate • Feb 22
OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside
Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.Narratiefupdate • Feb 07
OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside
Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.Narratiefupdate • Jan 24
OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside
Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.Narratiefupdate • Jan 10
OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential
Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.Narratiefupdate • Dec 22
OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.Narratiefupdate • Dec 08
OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.Narratiefupdate • Nov 24
OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum
Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.Analyseartikel • Oct 10
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Narratiefupdate • Aug 23
M&A And Competition Will Shape Risk And Opportunity In Healthcare
Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.Analyseartikel • May 23
Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...Analyseartikel • May 16
These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Nieuw narratief • May 08
Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency
Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.Analyseartikel • Apr 08
Little Excitement Around Omda AS' (OB:OMDA) Revenues
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...Analyseartikel • Jan 26
Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 21
The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...Analyseartikel • Nov 13
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analyseartikel • Jul 24
Returns At Omda (OB:OMDA) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analyseartikel • May 22
Omda's (OB:OMDA) Earnings Are Weaker Than They Seem
Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...Analyseartikel • Mar 24
Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified
Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Analyseartikel • Jan 24
Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)
When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...Analyseartikel • Nov 18
Omda's (OB:OMDA) Earnings May Just Be The Starting Point
Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...Analyseartikel • Jun 17
Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?
Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...Rendement voor aandeelhouders
| OMDA | NO Healthcare Services | NO Markt | |
|---|---|---|---|
| 7D | -2.6% | 0.01% | -1.9% |
| 1Y | -26.6% | -17.9% | 9.4% |
Rendement versus industrie: OMDA presteerde slechter dan de Norwegian Healthcare Services -sector, die het afgelopen jaar een rendement van -17.9 % opleverde.
Rendement versus markt: OMDA presteerde slechter dan Norwegian Market, dat het afgelopen jaar een rendement van 9.4 % opleverde.
Prijsvolatiliteit
| OMDA volatility | |
|---|---|
| OMDA Average Weekly Movement | 6.1% |
| Healthcare Services Industry Average Movement | 5.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in NO Market | 11.3% |
| 10% least volatile stocks in NO Market | 2.9% |
Stabiele aandelenkoers: OMDA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Norwegian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van OMDA is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 256 | Sverre Flatby | omda.com |
Omda AS levert software-oplossingen voor de gezondheidszorg in Noorwegen, Zweden, Denemarken, Finland en internationaal. Het biedt laboratoriuminformatiebeheersystemen bestaande uit Omda ProSang, een beheersysteem voor bloed, cellen en weefsels; en medische medicatieoplossingen bestaande uit Omda Cytodose, een beheersoplossing voor oncologische behandelingen. Het bedrijf biedt ook connected healthcare-oplossingen, waaronder Omda Cardio, een ECG- en diagnostische opslagtool; Omda CIMA, een mobiele app voor medische beeldvorming; Omda Media, een webgebaseerde oplossing voor medische beeldvorming; Omda Medimaker, een beeldbeheer- en workflowoplossing; Omda Picsara, een beeldbeheeroplossing; Omda Arcidis, een geïntegreerd teleradiologiesysteem; Omda Helsemail, een tool voor de overdracht van patiëntgegevens; Omda Plutus, een audit- en workflowmonitoringplatform; Omda S7, een beveiligd communicatieplatform voor e-zorg; en Omda XDS, een oplossing voor de opslag en het beheer van patiëntgegevens.
Omda AS Samenvatting
| OMDA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | NOK 750.58m |
| Inkomsten(TTM) | -NOK 35.92m |
| Inkomsten(TTM) | NOK 493.60m |
1.5x
P/S-verhouding-21.1x
Koers/WinstverhoudingIs OMDA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| OMDA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | NOK 493.60m |
| Kosten van inkomsten | NOK 258.75m |
| Brutowinst | NOK 234.85m |
| Overige uitgaven | NOK 270.77m |
| Inkomsten | -NOK 35.92m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 27, 2026
| Winst per aandeel (EPS) | -1.75 |
| Brutomarge | 47.58% |
| Nettowinstmarge | -7.28% |
| Schuld/Eigen Vermogen Verhouding | -2,394.2% |
Hoe presteerde OMDA op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
1.3%
Huidig dividendrendement-27%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/30 21:45 |
| Aandelenkoers aan het einde van de dag | 2026/06/30 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Omda AS wordt gevolgd door 3 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Kristian Støle | Carnegie Investment Bank AB |
| Emilie Engen | DNB Carnegie |
| Eirik Rafdal | DNB Carnegie |